Yeah good points all around. Just wanted to mention that even in the high quality phase 3 vaccine trials they found evidence that immunity acquired from previou

Yeah good points all around. Just wanted to mention that even in the high quality phase 3 vaccine trials they found evidence that immunity acquired from previous infection was effective at preventing subsequent symptomatic illness. Obviously that wasn't the primary goal so it was hardly even mentioned in the published papers, but you can see it in the raw data. For example, from the Moderna phase 3 RCT [1] see table S17 on page 42 [2]. Out of the people with natural immunity from previous infection: only 1 out of 337 unvaccinated people were reinfected, and 0 out of 343 vaccinated people were reinfected. Admittedly they didn't have a large number of participants in this cohort, so their statistical power was limited in this respect, perhaps contributing to their rational for not mentioning it as a primary finding. [1] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (Moderna) https://www.nejm.org/doi/full/10.1056/nejmoa2035389 https://www.nejm.org/doi/full/10.1056/nejmoa2035389 [2] Table S17. Vaccine Efficacy by SARS-COV-2 Status, Modified Intent-to-Treat https://www.nejm.org/doi/suppl/10.1056/NEJMoa2035389/suppl_file/nejmoa2035389_appendix.pdf https://www.nejm.org/doi/suppl/10.1056/NEJMoa2035389/suppl_f...